Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2021 | $19.00 | Buy | Lake Street |
Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair. "Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics," said David Perry, co-founder and chairman of Better Therapeutics. "Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.
8-K - Better Therapeutics, Inc. (0001832415) (Filer)
25-NSE - Mountain Crest Acquisition Corp II (0001832415) (Subject)
425 - Mountain Crest Acquisition Corp II (0001832415) (Subject)
Trading to commence on Nasdaq on Oct. 29, 2021, under the ticker symbol BTTX Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of its business combination with Mountain Crest Acquisition Corp II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly traded special purpose acquisition corporation or SPAC. The resulting combined company will commence trading its shares on Nasdaq under the ticker symbol "BTTX" on October 29, 2021. The shareholders of Mountain Crest Acquisition Corp II approved the transaction at a special meeting held on October
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) (the "Company"), a publicly traded special purpose acquisition company, announced today that in a special meeting of stockholders on October 27, 2021, its stockholders voted to approve its proposed business combination (the "business combination") with Better Therapeutics Inc. ("Better Therapeutics"), a company engaged in developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The business combination is expected to close on October 28, 2021, subject to the satisfaction of certain customary closing conditions. As part of the consummation o
NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD's registration statement on Form S-4 (File No. 333-255493) relating to the previously announced merger of MCAD and Better Therapeutics has been declared effective by the U.S. Securities and Exchange Commission as of October 12, 2021. MCAD also announced that it will hold its special m
SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G - Better Therapeutics, Inc. (0001832415) (Subject)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
Lake Street initiated coverage of Mountain Crest Acquisition Corp. II with a rating of Buy and set a new price target of $19.00